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Since the MAGE family’s identification, many tumour-associated
antigens (TAAs) have been discovered (van der Bruggen et al,
1991; Boon, 1993; Brichard et al, 1993; Kawakami et al, 1994;
Boon and van der Bruggen 1996), and the approach to use them as
targets of immunotherapy is now being rapidly developed. HER2 /
neu is a 185-kD transmembrane glycoprotein with the tyrosine
kinase activity, and its structure resembles that of the epidermal
growth factor receptor (Coussens et al, 1985; Yamamoto et al,
1986). HER2 / neu is broadly amplified or overexpressed in many
kinds of carcinomas, especially in adenocarcinomas that have not
been confirmed as a target for immunotherapy (Slamon et al,
1989; Williams et al, 1991; Yoshino et al, 1994; Albino et al, 1995;
Tsai et al, 1995; Lonn et al, 1996; Kapitanovic et al, 1997; Xia et
al, 1997; Brossart et al, 1998). In addition, the degree of amplifica-
tion is positively related to the poor prognoses of patients (Albino
et al, 1995; Lonn et al, 1996; Kapitanovic et al, 1997) and their
resistance to the anticancer chemotherapy (Tsai et al, 1995). In
colorectal carcinomas, a higher expression of HER2 / neu is found
in metastatic sites compared with primary regions (Kapitanovic et
al, 1997). In other words, HER2 / neu is one of the attractive and
expected antigen candidates for immunotherapy. 
In order to use HER2 / neu as a target of CTLs, some epitopes
restricted by HLA-A2 or -A3 were identified by some methods
(Fisk et al, 1994, 1995; Peoples et al, 1995; Kono et al, 1998;
Kawashima et al, 1999). However, to generalize the peptide-based
immunotherapy, the identification of the epitopes restricted by
other popular major histocompatibility (MHC) is required. 
To establish the immunotherapy for the colorectal carcinoma that
is still difficult to cure the patients in an advanced stage, the vaccine
therapy with dendritic cells (DCs) and tumour antigen peptides
might be an attractive and hopeful method (Romani et al, 1994;
Morse et al, 1999). Herein, we have newly identified an epitope
peptide of HER2 / neu restricted by HLA-A24, one of the most
common alleles in Japanese and Caucasians (Kubo et al, 1994;
Kondo et al, 1995; Date et al, 1996). And the CTLs induced by
peptide-pulsed autologous DCs specifically killed HLA-A24-posi-
tive and HER2 / neu- overexpressing colorectal carcinoma cell lines. 
MATERIALS AND METHODS 
Cell lines 
The TISI cells, human B-lymphoblastoid cell line expressing
HLA-A24, were used for peptide-mediated cytotoxicity assays.
The carcinoma cell line SKOV3 (HLA-A3 / A11, HER2 / neu+)
and its HLA-A24-transfected cell line SKOV3 / A24 were kindly
provided by Epimmunce Inc (San Diego, CA). The colon carci-
noma cell lines, HCT-15, HT29, and Colo320DM (all HLA-A24),
were supplied by Shionogi Pharmaceuticals (Osaka, Japan). These
cell lines were maintained in a tissue culture flask using RPMI
1640 containing HEPES and supplemented with antibiotics and
10% heat-inactivated fetal calf serum (Gibco BRL). The expres-
sion of HER2 / neu proteins was determined by flowcytometric
Mapping the HLA-A24-restricted T-cell epitope peptide
from a tumour-associated antigen HER2 / neu: possible
immunotherapy for colorectal carcinomas 
H Tanaka1, T Tsunoda1,2, I Nukaya3, A Sette3, K Matsuda1, Y Umano1, H Yamaue1, K Takesako3 and H Tanimura1
1Department of Surgery II, Wakayama Medical School, Wakayama, 641-0012, Japan; 2Department of Surgery and Bioengineering, Advanced Clinical Research
Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokane-dai, Minato-ku, Tokyo, 108-8639, Japan; 3Biotechnology Research Laboratories,
Takara Shuzo Co., Ltd. Otsu, Shiga 520-21, Japan 
Summary HER2 / neu is a potential antigen candidate for immunotherapy because of its correlation to a poor prognosis and high expressions
in many kinds of epithelial tumours. Especially in the colorectal carcinomas, the higher expression of HER2 / neu is recognized in metastatic
regions as well as in primary sites. Several CTL epitopes restricted by HLA-A2.1 and -A3 were identified so far, however epitopes restricted
by HLA-A24, that is one of the most common allele in Japanese and Caucasians, have not been identified. In this paper, we showed
identification of a CTL epitope peptide of HER2 / neu restricted by HLA-A24. HLA-A24 binding peptides selected by an analysis based on
HLA-A24 binding motifs were determined for their binding affinities to HLA-A24 molecules. The peptide with a sequence of RWGLLLALL
(position 8–16) named HE1 showed the highest affinity. We induced CTLs from CD8+ cells of HLA-A24 healthy donors by stimulation with
HE1-pulsed autologous dendritic cells. The CTLs showed cytotoxic activity against not only the peptide-pulsed target cells but also HLA-A24
colorectal tumour cell lines that endogenously overexpressed HER2 / neu. The antigen-specificity was confirmed by cold target inhibition
assay using HE1-pulsed target cells. In summary, HER2 / neu peptide, RWGLLLALL, may contribute to the induction of antitumour immunity
with the peptide-based immunotherapy for the colorectal carcinomas. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: CTL; epitope peptide; HER2 / neu; colorectal carcinoma 
94
Received 6 March 2000 
Revised 13 September 2000 
Accepted 20 September 2000 
Correspondence to: T Tsunoda
British Journal of Cancer (2001) 84(1), 94–99
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1547, available online at http://www.idealibrary.com on  http://www.bjcancer.comMapping epitope peptide of HER2 / neu 95
British Journal of Cancer (2001) 84(1), 94–99 © 2001 Cancer Research Campaign
analysis using the anti-HER2 / neu monoclonal antibody (Bender
MedSystems, Austria). 
Synthetic peptides 
Peptides were synthesized according to the standard solid phase
synthesis method and purified by reversed phase HPLC. The
purity ( > 90%) and the identity of the peptides were determined
by analytical HPLC and mass spectrometry analysis, respectively.
Peptides were dissolved in dimethylsulfoxide at 20 mg ml–1 and
stored at –20˚C. 
MHC binding assays 
The binding capacity of peptides to HLA-A24 molecules was
measured based on the inhibition of binding of a radiolabelled
standard peptide to purified MHC molecules as described by
Kondo et al (1995). Briefly, various concentrations of the test
peptides were incubated with 125I-labelled standard peptide
(sequence AYIDNYNKF) and purified and detergent-solubilized
HLA-A24 molecules in the presence of a mixture of protease
inhibitors and β -2-microglobulin (Scripps Laboratories, San
Diego, CA). The percentage of HLA-A24-bound radioactivity was
determined by gel filtration and the concentration of the test
peptides that inhibited 50% of the binding of the labelled peptide
(IC50) were calculated respectively. 
Primary CTL induction cultures 
Tissue culture-derived DCs were used as APC to trigger CTL
responses using MHC-binding peptides. DCs were generated in
vitro as described (Tsai et al, 1997; Nukaya et al, 1999). Briefly,
PBMC isolated from a normal volunteer (HLA-A24 / A2) by
Ficoll-Paque (Pharmacia, Piscataway, NJ) were separated by
adherence to a plastic tissue culture flask so as to enrich them for
the monocyte fraction. The monocyte-enriched population was
cultured in the presence of 1000 U ml–1 of GM-CSF (Genzyme)
and 2000 U ml–1 of IL-4 (Genzyme) in RPMI 1640 containing
HEPES and supplemented with 2 mM of L-glutamine, 1 mM of
sodium pyruvate and 0.1 mM of non-essential amino acids solu-
tion, 5% heat-inactivated AB human serum (all reagents from
BioWhittaker, Walkersville, MD), and antibiotics (RPMI / 5%
HS). After 7 days in the culture, the cytokine-generated DCs were
pulsed with 40µ g ml–1 of MHC-binding peptides in the presence
of 3µ g ml–1 ofβ 2-microglobulin for 4 h at 20˚C in PBS with 1%
bovine serum albumin. These peptide-pulsed DCs were then irra-
diated (5500 rads) and mixed at a 1:20 ratio with autologous CD8+
T cells, obtained by positive selection with Dynabeads M-450
CD8 (Dynal, Lake Success, NY) and Detachabead (Dynal). These
cultures were set up in 48-well plates; each well contained
0.25× 105 peptide-pulsed DC, 5 × 105 CD8+ cells and 10 ng ml–1
IL-7 (Genzyme) in 0.5 ml of RPMI / 5% HS. One day later, these
cultures were supplemented with IL-10 (R&D Systems,
Minneapolis, MN) to a final concentration of 10 ng ml–1. On days
7 and 14, the T cell cultures were further restimulated with the
autologous peptide-pulsed adherent APC. The adherent cells were
prepared each times. To prepare the adherent APC, 2× 106 irradi-
ated autologous PBMC in 0.5 ml of RPMI / 5% HS were added to
each well of 48-well plates. After incubation at 37˚C for 1.5 h, the
non-adherent cells were washed off, and the adherent cells were
incubated for 2 h with 0.2 µ g ml–1 of peptide and 3 µ g ml–1 of
β 2-microglobulin in a final volume of 0.25 ml of RPMI / 5% HS
per well. Supernatants of the responder cultures were aspirated and
RPMI / 5% HS was added to the total volume of 0.5 ml per well.
After removal of the excess peptide from the wells of the adherent
APC, the responder cultures were transferred to the corresponding
wells containing peptide-pulsed APC. Each individual well was
restimulated separately and on the day following each restimula-
tion, a final concentration of 10 ng ml–1 of IL-10 was added to each
culture. The cultures were fed every 2 to 3 days with RPMI / 5% HS
containing 10 U ml–1 of IL-2 (Shionogi, Osaka, Japan). Cytotoxicity
was tested after 2 and 4 rounds of peptide stimulation on day 21 and
day 36 using peptide-pulsed TISI cells. Responder cells in the posi-
tive wells for peptide eradication were expanded as described below
and tested for their cytotoxicity to SKOV3 / A24 tumour cells, which
naturally produce and process the HER2 / neu molecule.
CTL cytotoxicity assays 
Adherent target cells were detached from tissue culture flasks with
trypsin-EDTA. All cells were labelled with 100 µ Ci of 51Cr
(Dupont) per 3 × 106 cells for 1 h at 37˚C. Peptide-pulsed targets
were prepared by incubating the cells at 5 × 105 cells ml–1 with 10
µ g ml–1 of the peptide for 16 h at 37˚C. Target cells were washed
by centrifugation and mixed with effectors in a final volume of 0.2
ml in round-bottom microtitre plates. The plates were centrifuged
(2 min at 400 g) to increase cell-to-cell contact and placed in a CO2
incubator at 37˚C. After 4 h of incubation, 0.1 ml of the super-
natant was removed from each well and the radioactivity was
determined in a gamma counter. In the initial screening for the
presence of cytolytic activity in each well of the 48-well minicul-
tures, the effector cells were routinely not counted. However,
sample counting of these cells indicated that effector to target
(E:T) ratios in these assays were in the range of 10:1 to 1:1. To
eliminate any non-specific lysis due to NK-like effectors, the
cytolytic activity was tested in the presence of a 30-fold excess of
unlabelled K562 cells. Antigen specificity was confirmed by cold
target inhibition experiments, which utilized unlabelled TISI cells
that were pulsed with peptide (10 µ g ml–1 for 16 h at 37˚C) to
compete for the recognition of 51Cr-labelled HCT-15 tumour cells. 
The percentage of specific cytotoxicity was determined by
calculating the percentage of specific 51Cr release according to the
following formula: (cpm of the test sample release – cpm of the
spontaneous release) / ((cpm of the maximum release – cpm spon-
taneous release)) × 100. The spontaneous release was determined
by incubating the target cells alone, in the absence of effectors, and
the maximum release was obtained by incubating the targets with
1N-HCl. All determinants were done in duplicates, and the SEMs
were consistently below 10% of the value of the mean. 
CTL expansion procedure 
Responder cells or CTL lines were expanded in tissue culture
following a method similar to the one described by Riddell et al
(Walter et al, 1995; Riddel et al, 1996). A total 5 × 104 CTL were
resuspended in 25 ml of RPMI / 5% HS with 25 × 106 irradiated
(3300 rads) PBMC and 5 × 106 irradiated (8000 rads) Epstein-
Barr virus-transformed B-lymphoblastoid cell line EHM cells
(HLA-A3 / 3) in the presence of 30 ng ml–1 of anti-CD3 mono-
clonal antibodies. One day after initiating the cultures, 120 lU ml–1
of IL-2 were added to the cultures. The cultures were fed with
fresh RPMI / 5% HS containing 30 IU ml–1 of IL-2 on days 5, 8and 11 and were split if the T-cell concentration reached numbers
> 1.5 × 106 ml-1. On average, approximately 1 to 2 × 107 CTL
were obtained by days 12–14. 
RESULTS 
Determination of the HLA-A24 binding peptides from
HER-2 / neu 
The amino acid sequence of HER2 / neu (Yamamoto et al, 1986)
was scanned for peptides having a length of 9 or 10 amino acids,
containing the HLA-A24 binding motif (Y, F or W at position 2
and F, L, I, W or M at the C-terminus) (Kubo et al, 1994). Of a
total of 15 motif-including peptides tested for HLA-A24 binding,
5 peptides were found to bind to the purified HLA-A24 molecules
with a high affinity (IC50 < 50 nM, Table 1) and 10 bound to the
HLA-A24 molecules with an intermediate to low range of affini-
ties (IC50 of 50–500 nM, data not shown). 
CTLs induced with HE1 peptide-pulsed DC indicated
peptide-specific and HLA-A24 restricted cytotoxicity 
We selected the peptide RWGLLLALL called HE1, (located at
position 8 to 16 from the N-terminus of HER2 / neu protein),
because it showed the distinctive binding to the purified HLA-A24
molecules. This peptide was studied for its capacity to elicit the
CTL response by primary in vitro immunization of CD8+ T cells
stimulated with the peptide-pulsed autologous DCs using PBMCs
from two donors. After 4 rounds of the restimulation with antigen,
several wells showed the positive cytotoxic activity. We chose the
CTLs in one well which showed the strongest peptide-specific
cytotoxic activity in each donor. After in vitro expansion, the
CTLs from one donor lysed HE1-pulsed TISI cells but not
unpulsed TISI cells which HE1 was not pulsed (% specific lysis at
E / T= 5, 50% for TISI pulsed with peptide and 4% for TISI with-
out peptide, Figure 1A). The cytotoxic activity of the CTL against
HE1-pulsed TISI could be observed even at low E / T ratio. The
CTLs lysed HER2 / neu-overexpressing ovarian carcinoma cell
line SKOV3 / A24 but not its parent cell line SKOV3 (% specific
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Table 1 Binding affinity of HER-2/neu peptides to HLA-A24 molecules 
Code Position Peptide sequence IC50 (nM) 
HE1 8–16 RWGLLLALL 4.5
HE2 780–788 PYVSRLLGI 34 
HE3 952–960 VYMIMVKCW 36 
HE4 440–448 AYSLTLQGL 45 
HE5 907–915 SYGVTVWEL 48 
The HER[8–16]: RWGLLLALL (abbreviated HE1) showed the strongest
binding to the purified HLA-A24 molecules. 
Figure 1 Cytotoxic activity against peptide-pulsed target cells and ovarian carcinoma cell lines expressing HER2 / neu. The CTLs expanded after 4 cycles of
restimulations with peptides were tested for their cytotoxic activity. (A) The recognition of peptide (HE1)-pulsed TISI by the CTSs.:    , TISI pulsed with peptide
(HE1);   , TISI without peptide. (B) Recognition of HLA-A24 transfected SKOV3, ovarian cancer cell line that overexpresses HER-2/neu: ,   , SKOV3 (ovarian
cancer, A3/A11, HER2/neu+);    , SKOV3/A24 (ovarian cancer, A24+, HER2/neu+) 
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Figure 2 Expression of HER2 / neu for colorectal carcinoma cell lines by
FACS. The dotted line indicates the secondary antibody alone (FITC
conjugated controlled antibody). The black line indicates that
anti-HER2 / neu monoclonal antibody plus the secondary antibody 
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lysis at E / T = 20, 19% and 4%, respectively) (Figure 1B). These
results indicate that the CTL induced by HE-1 peptide showed
cytotoxicity with peptide-specificity and HLA-A24-restricticity. 
Cytotoxic activity of the CTLs against colorectal
carcinoma cell lines in HER2 / neu specific and 
HLA-A24-restricted manner 
To clarify the cytotoxic activity of the CTLs against colorectal
carcinoma cell lines that endogenously express HER2 / neu, we
used 3 colorectal carcinoma cell lines. We tested for expression of
HER2/neu by way of flow cytometry. Expression of HER2/neu
was shown to be stronger at metastatic sites of colorectal tumours
than at primary lesions (Kapitanovic et al, 1997). Colorectal carci-
noma cell lines, HCT 15 and HT29, expressed HER2/neu highly,
whereas Colo320DM did very weakly (Figure 2). Then, cytotoxic
activity of the CTLs induced by HE1 against these cell lines was
investigated. The CTLs showed the distinct cytotoxic activity
against HLA-A24-positive and HER2/neu-overexpressing cell
lines, HT29 and HCT-15 (% specific lysis at E/T = 30, 74% and
46%, respectively, Figure 3). On the other hand, the cytotoxic
activity of the CTLs against Colo320DM and SKOV3 that lacked
either HLA-A24 or strong expression of HER2/neu, was very
weak or absent, 8% and 0%, respectively (Figure 3). Furthermore,
the cytotoxic activity against HCT-15 was inhibited by cold targets
(peptide-pulsed TISI), but not by TISI without peptide, showing
that the cytotoxicity was specific to HER2/neu (Table 2). 
DISCUSSION 
Adenocarcinomas including colorectal carcinomas have not been
considered as the suitable candidates for antitumour immuno-
therapy because of their low immunogenicity, compared with
malignant melanoma (Mukherji et al, 1995; Hu et al, 1996;
Rosenberg et al, 1998). On the other hand, a large number of
patients die of various kinds of adenocarcinomas, therefore, the
antigens expressed in adenocarcinomas are eagerly expected to be
the targets for immunotherapy. 
Especially HER2/neu is a TAA that is expressed in various
kinds of carcinomas including breast, ovary, and colorectal carci-
noma (Slamon et al, 1989; Williams et al, 1991; Yoshino et al,
1994; Albino et al, 1995; Tsai et al, 1995; Lonn et al, 1996;
Kapitanovic et al, 1997; Xia et al, 1997; Brossart et al, 1998). In
addition, this antigen has some characteristics that its strong
Table 2 Antigen specificity of the CTLs by cold target inhibition assay 
Exp. Inhibitor/Target Inhibitor (%) % Inh. 
TISI alone TISI + HE1 
1 3 18.3 17.9 2.2 
10 18.4 12.8 30.4 
2 30 17.1 7.4 56.7 
As a hot target, HCT15 (HER2 / neu and HLA-A24 positive) cells were
labelled with 51Cr and mixed with TISI (HLA-A24 positive LCL) pulsed with
HE1 and TISI without peptide as cold targets. The results were indicated as a
percentage of specific lysis at the E / T ratio of 10. 
Figure 3 Tumour reactivity and antigen specificity of HLA-A24-restricted HE1-specific CTL. The HE1-specific CTL expanded after 4 cycles of restimulations
with peptide was used as effector cells to test the cytotoxic activity of the following target cell lines:    , HCT-15 (colon carcinoma, A24+, HER2/neu+);    , HT29
(colon carcinoma, A24+, HER2 / neu+);   , SKOV3 (ovarian carcinoma, A24-, HER2/neu+);   , Colo320DM (colon carcinoma, A24+, HER2 / neu-) 
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SKOV3expression at the primary site of a patient has related to the poor
prognosis (Lonn et al, 1996; Xia et al, 1997), and that the expres-
sion of metastatic sites is stronger than the primary sites
(Kapitanovic et al, 1997). From these facts, HER2/neu has been
considered to be one of the potential tumour antigens not only for
CTL therapy but also for antibody therapy (Bacus et al, 1992;
Baselga et al, 1998; Ward et al, 1999). 
Some HLA-A2 or -A3-restricted peptides of HER2/neu that
elicit the CTL activity have identified so far (Fisk et al, 1994,
1995; Peoples et al, 1995; Kono et al, 1998; Kawashima et al,
1999), however the epitope peptide that is restricted by HLA-A24
has not been identified yet. HLA-A24 is one of the most popular
HLA allele in Japanese ( > 60%) and also in Caucasian (Kubo et
al, 1994; Kondo et al, 1995; Date et al, 1996). Moreover, most of
their microallele consist of HLA-A*2402. Thus we have little
necessity to consider the variations of the motifs between microal-
leles and this is a distinctive advantage compared with other
popular HLA allele like HLA-A2. 
In this study, we identified the HLA-A24-restricted epitope
peptide of HER2/neu (Kapitanovic et al, 1997) (HE1: RWGLL-
LALL) that elicited the antigen-specific cytotoxicity in HLA-A24-
restricted manner. At first, we investigated the affinity to
solubulized HLA-A24 molecules of over 20 peptides having
binding-motifs to HLA-A24, considering that the peptides having
high affinity to HLA molecules could be presented by APCs more
frequently. Then we tested 5 high-binding peptides shown in Table
1 for the CTL induction activity, with the result that only the CTLs
stimulated with HE1 showed the cytotoxicity against the peptide-
pulsed TISI (data not shown). Thus we chose the HE1 to the
further analyses. In the in vitro primary induction with DCs, CTL
lines induced by HE1 showed the considerable cytotoxic activity.
The generated CTL lines showed specific cytotoxicity not only
against the peptide-pulsed target cells but also against HLA-A24
colorectal carcinoma cell lines overexpressing HER2/neu. Fur-
thermore, they did not show the cytotoxic activity against the cell
lines that lacked either of them. In the cold target inhibition assay,
the cytotoxicity against a colon carcinoma cell line HCT-15 was
inhibited by the HE1-pulsed TISI and was not by TISI without
peptide. Based on these results, we finally determined the HE1
peptide as one of an epitope peptide restricted by HLA-A24. 
In this study, it is clear that DCs had a very important role as
APCs for inducing peptide-specific CTLs. DCs have been consid-
ered as efficient tools to induce the immune responses against
cancers even in vivo (Reeves et al, 1996; Hart, 1997; Nestle et al,
1998). We showed HER2/neu-specific CTLs could be induced by
autologous DCs and HE1. This result will be helpful for clinical
applications of colorectal carcinoma vaccines in the near future. In
order to promote the clinical response for cancer vaccine, it is
important to map as many epitope peptides as possible. Clinical
studies will be necessary to define the optimal setting, maybe the
situation of minimal residual disease or adjuvant therapy, as well
as adequate vaccination procedures and antigen concentrations. 
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